{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:47:32Z","timestamp":1779317252252,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MEXT KAKENHI","award":["18K15096"],"award-info":[{"award-number":["18K15096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12282-026-01837-4","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:04:15Z","timestamp":1771833855000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-3775","authenticated-orcid":false,"given":"Fumi","family":"Nozaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Hirotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Nishimaki-Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Ohni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Mart\u00ednez-S\u00e1ez","year":"2020","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T, Adamo B, Vidal M, Gonz\u00e1lez-Farr\u00e9 B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22:45. https:\/\/doi.org\/10.1186\/s13058-020-01284-9.","journal-title":"Breast Cancer Res"},{"key":"1837_CR2","volume-title":"Breast tumours","author":"WHO Classification of Tumours Editorial Board","year":"2019","unstructured":"WHO Classification of Tumours Editorial Board. Breast tumours. 5th ed. Lyon, France: IARC; 2019.","edition":"5th ed"},{"key":"1837_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","volume":"196","author":"K Reinhardt","year":"2022","unstructured":"Reinhardt K, St\u00fcckrath K, Hartung C, Kaufhold S, Uleer C, Hanf V, et al. PIK3CA-mutations in breast cancer. Breast Cancer Res Treat. 2022;196:483\u201393. https:\/\/doi.org\/10.1007\/s10549-022-06637-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1837_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s12276-023-01030-z","volume":"55","author":"JY Kim","year":"2023","unstructured":"Kim JY, Park S, Cho EY, Lee JE, Jung HH, Chae BJ, et al. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer. Exp Mol Med. 2023;55:1451\u201361. https:\/\/doi.org\/10.1038\/s12276-023-01030-z.","journal-title":"Exp Mol Med"},{"key":"1837_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41379-020-0589-x","volume":"33","author":"X Sun","year":"2020","unstructured":"Sun X, Zuo K, Yao Q, Zhou S, Shui R, Xu X, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod Pathol. 2020;33:2473\u201382. https:\/\/doi.org\/10.1038\/s41379-020-0589-x.","journal-title":"Mod Pathol"},{"key":"1837_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"1837_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"key":"1837_CR8","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2214131.","journal-title":"N Engl J Med"},{"key":"1837_CR9","doi-asserted-by":"crossref","unstructured":"Breast cancer expert committee of the national quality control center for cancer; Expert Committee on Cancer Prevention and Treatment of the Health China Research Center; Society of Clinical Research on Oncology Medications of the China Anti-Cancer Association; Society of Onco-Pathology of the China Anti-Cancer Association. Expert consensus on the clinical application of PI3K\/AKT\/mTOR inhibitors in the treatment of breast cancer 2025 Edition). Cancer Innov 2025;4:e70008. doi: 10.1002\/cai2.70008.","DOI":"10.1002\/cai2.70008"},{"key":"1837_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10078-5","volume":"22","author":"M Fillbrunn","year":"2022","unstructured":"Fillbrunn M, Signorovitch J, Andr\u00e9 F, Wang I, Lorenzo I, Ridolfi A, et al. PIK3CA mutation status, progression and survival in advanced HR + \/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22:1002. https:\/\/doi.org\/10.1186\/s12885-022-10078-5.","journal-title":"BMC Cancer"},{"key":"1837_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48814","volume":"6","author":"P Zagami","year":"2023","unstructured":"Zagami P, Fernandez-Martinez A, Rashid NU, Hoadley KA, Spears PA, Curigliano G, et al. Association of PIK3CA mutation with pathologic complete response and outcome by hormone receptor status and intrinsic subtype in early-stage ERBB2\/HER2-positive breast cancer. JAMA Netw Open. 2023;6:e2348814. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.48814.","journal-title":"JAMA Netw Open"},{"key":"1837_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100342","volume":"10","author":"B Nami","year":"2018","unstructured":"Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers. 2018;10:342. https:\/\/doi.org\/10.3390\/cancers10100342.","journal-title":"Cancers"},{"key":"1837_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-019-05239-3","volume":"176","author":"C Gao","year":"2019","unstructured":"Gao C, Yuan X, Jiang Z, Gan D, Ding L, Sun Y, et al. Regulation of AKT phosphorylation by GSK3\u03b2 and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat. 2019;176:291\u2013301. https:\/\/doi.org\/10.1007\/s10549-019-05239-3.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01837-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:12:23Z","timestamp":1779275543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01837-4","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study design was approved by the Institutional Review Board of Nihon University School of Medicine (approval number: RK-170509-4) and followed the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Written informed consent was obtained from all participants prior to initiation of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}